KPV Preclinical

What It Is

KPV is a tripeptide consisting of lysine-proline-valine (Lys-Pro-Val). It is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH) — specifically residues 11–13 of the parent 13-amino-acid α-MSH sequence. The broader α-MSH molecule is a well-characterized anti-inflammatory and immunomodulatory peptide, and the classic assumption for years was that α-MSH's effects required binding to melanocortin receptors (MC1R–MC5R). The surprise finding, developed across a series of papers by the Luger group in Münster and the Dalmasso/Merlin group at Emory, was that the tripeptide KPV retained the anti-inflammatory activity of α-MSH while explicitly NOT requiring melanocortin receptor engagement. The anti-inflammatory effect is mediated through PepT1 (the intestinal peptide transporter) and downstream NF-κB pathway inhibition — a mechanism that operates entirely independent of the melanocortin receptor family.

This mechanism matters for two reasons. First, it explains why KPV is orally bioavailable — PepT1 is the major intestinal oligopeptide transporter, and KPV is a good substrate. Oral α-MSH would be degraded; oral KPV is absorbed. Second, it means KPV does not produce the melanocortin-receptor-mediated effects of α-MSH and its analogs — no pigmentation, no sexual effects, no appetite suppression, no BP elevation. The phenotype is narrowly anti-inflammatory with minimal off-target pharmacology, which is unusual for bioactive peptides in the optimization space.

The Dalmasso et al. 2008 Gastroenterology paper (PMID 18061177) established KPV as a PepT1-mediated anti-inflammatory tripeptide in two mouse colitis models (DSS-induced and TNBS-induced), and Kannengiesser et al. 2008 (PMID 18092346) replicated the effect in additional IBD models from a separate research group. Since then, KPV has been explored in preclinical models of ulcerative colitis, Crohn's disease, atopic dermatitis, psoriasis, ocular inflammation, and general skin inflammation. In the community optimization space, KPV has become one of the most-used anti-inflammatory peptides, particularly for IBD-spectrum gut conditions and chronic skin inflammation, often stacked with BPC-157.

As of April 2026, KPV has no published Phase 2 or Phase 3 human clinical trial for any indication. Community use is extrapolated from the preclinical literature and from α-MSH's broader immunomodulatory profile. The mechanism is well-established at the bench level; the clinical endpoint validation in humans is still pending.

Mechanism of Action

KPV's mechanism is narrowly focused and now fairly well-characterized at the molecular level, despite the absence of large-scale human data.

• PepT1-mediated cellular uptake — KPV is a substrate for PepT1 (SLC15A1), the di- and tri-peptide transporter highly expressed in intestinal epithelium and upregulated in inflamed colon and on activated immune cells. This uptake mechanism is the primary route for KPV entry into cells that matter for its anti-inflammatory effect (Dalmasso et al., 2008; PMID 18061177).
• NF-κB pathway inhibition — Once inside cells, KPV inhibits NF-κB activation, the master transcriptional regulator of pro-inflammatory cytokine production. Reduced NF-κB nuclear translocation reduces transcription of TNF-α, IL-6, IL-8, IL-1β, and other inflammatory mediators.
• MAPK pathway inhibition — KPV reduces activation of p38, ERK, and JNK MAP kinases. These pathways cooperate with NF-κB to amplify inflammatory responses; blocking both gives KPV a broader anti-inflammatory footprint than blockade of either alone.
• Pro-inflammatory cytokine reduction — Downstream of NF-κB and MAPK inhibition, KPV reduces TNF-α, IL-6, IL-8, IL-1β, IL-18, and IFN-γ expression in activated immune cells and inflamed tissues.
• Non-melanocortin-receptor mechanism — Critically, KPV does not bind MC1R, MC3R, MC4R, or MC5R with appreciable affinity. This means it does not produce pigmentation, sexual function effects, appetite suppression, or BP elevation like its larger cousin α-MSH or analogs (MT-II, PT-141).
• Epithelial barrier integrity — Reduces paracellular permeability in inflamed gut epithelium; preserves tight junction protein expression.
• Mast cell stabilization — Reduces mast-cell-derived histamine and tryptase release — mechanism for skin inflammation (atopic dermatitis) benefit.
• Macrophage polarization — Shifts macrophages from M1 (pro-inflammatory) toward M2 (resolving) phenotype in inflamed tissue.
• T-cell modulation — Reduces Th1 and Th17 cytokine production without broad immunosuppression; preserves immune surveillance.
• Anti-microbial activity (α-MSH heritage) — Inherited from the parent α-MSH molecule, KPV has modest direct anti-microbial activity against some bacterial pathogens.
• PepT1 upregulation in disease — PepT1 expression is upregulated in inflamed colon and on activated immune cells, producing a "feedback" targeting effect — KPV concentrates preferentially in the tissue compartments where it is most needed.

What the Research Shows

The KPV preclinical evidence base is focused and mechanistically coherent, concentrated around inflammatory bowel disease and skin inflammation.

• PepT1-mediated anti-colitis (Dalmasso et al., Gastroenterology 2008; PMID 18061177) — Foundational paper establishing PepT1-mediated KPV uptake and anti-inflammatory effect in DSS- and TNBS-induced colitis. Showed oral KPV significantly reduced colonic inflammation markers.
• IBD model efficacy (Kannengiesser et al., Gastroenterology 2008; PMID 18092346) — Independent replication from the Luger group in Münster. Melanocortin-derived tripeptide KPV showed anti-inflammatory potential in murine models of inflammatory bowel disease. Reduction in colonic damage and inflammatory cytokines.
• Alpha-MSH anti-inflammatory review (Luger et al., Ann N Y Acad Sci) — Broader framework placing KPV within the α-MSH anti-inflammatory family.
• PepT1 in colitis-associated cancer (Cell Mol Gastroenterol Hepatol 2016) — Demonstrated therapeutic benefit of PepT1-mediated KPV in colitis-associated cancer mouse model.
• Hyaluronic-acid nanoparticle delivery (Coco et al., 2017; PMC5498804) — Orally targeted delivery of KPV via HA-functionalized nanoparticles efficiently alleviated ulcerative colitis in mouse model. Proof-of-concept for targeted delivery formulation.
• Core/C-terminal α-MSH dissection — Research dissecting the anti-inflammatory activity of core and C-terminal (KPV) α-MSH peptides established that the C-terminal KPV retains the anti-inflammatory effect without requiring melanocortin receptor binding.
• Skin inflammation / atopic dermatitis — Preclinical studies showing KPV reduces atopic dermatitis-type inflammation in mouse models; mechanism involves mast cell stabilization and cytokine reduction.
• Keratinocyte NF-κB inhibition — Cell culture studies demonstrating KPV reduces inflammatory cytokine production in keratinocytes under TNF-α stress and fine-particulate exposure.
• Psoriasis models — Preclinical reports of topical KPV reducing psoriasiform inflammation in mouse models.
• Ocular inflammation (anterior uveitis) — Preclinical work on KPV-family peptides in ocular inflammation models.
• Wound healing (anti-inflammatory component) — Complementary role of KPV in the resolution phase of wound healing via inflammation control.
• Anti-microbial activity — Modest direct anti-bacterial activity against some pathogens; inherited from α-MSH.

Human Data

Human evidence for KPV is minimal:

• Alpha-MSH in humans (parent molecule) — Elevated endogenous α-MSH observed in some inflammatory conditions as a counter-regulatory response. Provides indirect support for the anti-inflammatory framework.
• No published Phase 1 pharmacokinetic study of KPV specifically — Surprising gap given the preclinical enthusiasm. PepT1 substrate pharmacokinetics in humans is extrapolated from general PepT1 pharmacology.
• No Phase 2 or Phase 3 RCT — For any indication, including IBD, UC, CD, atopic dermatitis, or psoriasis.
• Open-label and case-report community use — Accumulated practitioner experience in IBD, gut inflammation, allergic skin conditions, and allergic asthma. Not validated endpoint data.
• KPV-containing topical formulations — Commercial cosmetic and wound-healing products containing KPV exist. Limited clinical endpoint data.
• Nanoparticle-targeted delivery trials — Emerging pharmaceutical development of HA-nanoparticle-targeted KPV; preclinical only as of April 2026.

This evidence gap is the central limitation of KPV's profile. The preclinical mechanism and data are strong; the human clinical validation is thin. The compound has been used in community settings for ~15 years without a Phase 2 program materializing — likely a combination of funding challenges (small tripeptides don't fit large-pharma economics) and the absence of regulatory incentive to develop it.

Dosing from the Literature

Dosing in the mouse models is typically in the 100–500 μg/kg/day range via oral gavage. Human dosing is extrapolated community practice.

Reconstitution & Storage

KPV is supplied as lyophilized powder. For oral/nasal use, can be reconstituted in BAC water or sterile water; for SubQ, BAC water.

• Reconstitution — Inject water slowly down the vial wall at 45°. Swirl; do not shake. Clear colorless solution.
• Oral administration — Hold the measured oral volume sublingually for 30–60 seconds before swallowing. Alternatively, swallow directly — PepT1 absorption from the small intestine is the dominant pathway.
• SubQ administration — 29–31G insulin syringe, 45° SubQ into abdomen or thigh. Rotate sites.
• Storage — Unreconstituted: 2–8°C preferred. Reconstituted: 2–8°C, use within 28 days.
• Timing — Oral: empty stomach or 30+ minutes before food for optimal PepT1 engagement. SubQ: any time of day; split doses through day.
• Inspection — Discard if cloudy, discolored, or contaminated.

→ Use the Kalios Peptide Calculator for exact dosing volumes

Side Effects & Risks

KPV has among the cleanest safety profiles of any peptide in the community space — a combination of its short tripeptide length, narrow mechanism (NF-κB inhibition), and absence of melanocortin receptor engagement.

• Injection site reactions — Mild; self-limited. Minimal at typical community doses.
• GI discomfort (oral) — Occasional mild GI upset with oral dosing; usually well-tolerated.
• Headache (rare) — Occasionally reported at higher doses.
• No pigmentation effects — Unlike α-MSH, MT-II, or PT-141 — KPV does not engage MC1R, so no tanning, no melanocytic stimulation, no nevus effects.
• No sexual function effects — Unlike PT-141 or MT-II — KPV does not engage MC4R.
• No appetite suppression — Unlike MC4R agonists.
• No BP elevation — Unlike MT-II.
• Immunosuppression concern (theoretical) — As an anti-inflammatory compound, very chronic or high-dose use could theoretically blunt normal immune response. Preclinical data do not show significant immune suppression at typical doses, and α-MSH's broader immunomodulatory role is regulatory rather than blanket suppressive.
• Drug interactions — Minimal documented. PepT1 substrate interactions with other PepT1 substrates (β-lactam antibiotics, valacyclovir) are theoretical; not clinically reported.
• Pregnancy / lactation — Not studied; avoid.
• Active infection — Reduced cytokine response could theoretically impair infection control; avoid during active bacterial, viral, or fungal infection.
• Purity / sourcing — Tripeptide is extremely simple to synthesize; gross purity problems are uncommon. Third-party HPLC + mass spec COAs remain the standard.
• Regulatory status — Not FDA-approved; not scheduled. Research-chemical supply.
• WADA status — Not specifically listed.

Supportive Nutrition & Supplements

For inflammatory conditions, nutritional foundations matter substantially. KPV is a modulator on top of foundational anti-inflammatory support.

• Omega-3 (2–3 g EPA/DHA) — Resolves inflammation via specialized pro-resolving mediators (SPMs). Mechanistically complementary to KPV's NF-κB-inhibition mechanism.
• Vitamin D (target 40–60 ng/mL) — Immunomodulation; associated with lower IBD risk and severity.
• Zinc (15–25 mg) — Immune and epithelial barrier support; zinc deficiency is common in IBD.
• Magnesium (300–400 mg) — General anti-inflammatory support.
• Curcumin (500 mg BID, bioavailability-enhanced) — NF-κB pathway inhibitor; mechanism-parallel to KPV. Evidence for UC maintenance of remission.
• Glutamine (5–10 g) — Intestinal epithelial fuel; supports gut barrier function.
• Probiotics (multi-strain) — Particularly for IBD-spectrum use; microbiome modulation complements KPV's anti-inflammatory effect.
• Short-chain fatty acids (butyrate) — Colonocyte fuel; supports epithelial barrier and reduces inflammation.
• Dietary exclusions (IBD context) — Low-FODMAP, specific carbohydrate diet, or elemental diet may complement KPV depending on the specific GI condition.
• Stress management — Chronic stress drives HPA/SNS activation that opposes the anti-inflammatory state KPV supports.
• Things to avoid — Chronic NSAIDs in gut-inflammation contexts, chronic alcohol (disrupts gut barrier), smoking (strong adverse effect on IBD; particularly Crohn's), highly processed food (inflammatory).

What to Expect — Timeline

Individual response varies. KPV's effects are gradual anti-inflammatory rather than acute.

• Day 1–3 — Usually no immediate subjective change. Some users with active gut inflammation report earlier reduction in cramping or urgency.
• Week 1–2 — Users with acute gut inflammation commonly report subjective improvement in stool consistency, urgency, and cramping. Users targeting skin conditions may see reduced itch or redness.
• Week 2–4 — Peak effect window for most responders. GI: reduced bowel frequency, improved stool consistency, reduced visible blood if previously present, reduced abdominal pain. Skin: reduced erythema, reduced eczematous flares.
• Week 4–8 — Plateau. Continued dosing maintains effect.
• Post-cycle — Benefits often persist for weeks after cessation in users who responded. Some users describe persistent improvement suggesting the intervention helped reset an inflammatory pattern that doesn't immediately return.
• Non-responders — Real. Users with structural gut pathology (e.g., stricturing Crohn's, severe UC) often find KPV insufficient. Users with pure inflammatory features tend to respond better.
• IBD context — KPV is not a replacement for anti-TNF, JAK inhibitor, or other disease-modifying IBD therapy. It is at best an adjunct for inflammation control. Never stop prescription IBD therapy to try KPV.
• Allergic / skin context — Users with atopic dermatitis, contact dermatitis, or mast-cell-mediated skin inflammation often report best subjective effect. Chronic urticaria response is variable.
• If you feel worse — Worsening GI symptoms, new skin reactions, fever, systemic symptoms — stop and evaluate. KPV doesn't have many documented adverse effects; new symptoms warrant attention.

Quick Compare — KPV vs BPC-157 vs Alpha-MSH vs Afamelanotide

The most relevant comparators are BPC-157 (gut-healing peptide with overlapping IBD use case), the parent α-MSH molecule, and afamelanotide (FDA-approved α-MSH analog for EPP).

Practical interpretation:

• KPV vs BPC-157 — Different mechanisms (NF-κB inhibition vs growth factor / angiogenic signaling). Complementary in gut-inflammation protocols — commonly combined. KPV focuses on inflammation control; BPC-157 supports healing and repair.
• KPV vs α-MSH — KPV retains α-MSH's anti-inflammatory activity without the melanocortin-receptor-mediated side effects (pigmentation, sexual, BP). For anti-inflammatory use, KPV is mechanism-clean; α-MSH itself is not pharmaceutically used.
• KPV vs afamelanotide — Different use cases entirely. Afamelanotide is a photoprotection drug for EPP; KPV is an anti-inflammatory research peptide.
• Combining in IBD / gut inflammation — KPV + BPC-157 + L-glutamine + curcumin is a common community "gut stack." Evidence for combined benefit is practitioner-level.
• Combining in skin inflammation — Topical KPV + topical GHK-Cu is a common community "skin stack" for atopic and rosacea-type inflammation.
• Best-fit use — KPV for narrowly anti-inflammatory signaling without melanocortin-receptor side effects; BPC-157 for repair + gut protection with more complex mechanism; afamelanotide for EPP under dermatology care.

→ See BPC-157 profile  •  → See Afamelanotide profile  •  → See PT-141 profile

Practical User Notes

• Oral is practical — KPV's PepT1-mediated absorption is unusual among peptides. Oral 200–500 μg 1–3x daily is a legitimate route. Take on empty stomach for best absorption.
• Sublingual hold (30–60 seconds) before swallowing — Common community practice; unclear if mucosal absorption is meaningful, but low cost to add.
• SubQ for systemic / non-GI applications — Skin, systemic inflammation, autoimmune-adjacent conditions.
• Combine with BPC-157 for gut protocols — KPV provides inflammation control; BPC-157 provides mucosal healing and angiogenic support. Standard gut-stack combination.
• Combine with curcumin and omega-3 — Mechanism-complementary, low-cost, low-risk adjuncts. Reasonable to layer.
• Start at 200 μg 2x/day oral — Assess at 2–4 weeks. Escalate to 3x/day if needed.
• Don't stop prescription IBD therapy — KPV is an adjunct, not a replacement for anti-TNF, mesalamine, budesonide, or JAK inhibitors in established IBD.
• Track symptoms objectively — Bristol stool scale, flare frequency, symptom diary. Subjective recall is unreliable.
• Sourcing — Tripeptide is easy to synthesize. Third-party HPLC + mass spec COAs are the floor.
• Storage — 2–8°C reconstituted; use within 28 days.
• Cycle if desired — 4–8 weeks on, 2–4 weeks off is conservative. No documented tachyphylaxis.
• Pair with lifestyle — Stress management, sleep, diet, smoking cessation (particularly in Crohn's) are the foundational levers. KPV amplifies; it doesn't rescue a misaligned lifestyle.
• Red flags to stop — New fever, active infection, worsening of the target condition, new skin eruptions. Stop and evaluate.

Bloodwork & Monitoring

KPV monitoring is minimal given the clean safety profile. For inflammatory conditions being treated:

• Baseline CMP / CBC — Standard.
• hsCRP / ESR — Inflammation markers; baseline and periodically.
• Fecal calprotectin (IBD context) — Objective colonic inflammation marker. Baseline and after 8 weeks.
• Colonoscopy / imaging (IBD context) — As clinically indicated by IBD severity.
• Skin photography (dermatologic use) — Standardized photos capture eczema or psoriasis changes objectively.
• IgE (atopic context) — Relevant in atopic dermatitis monitoring.
• Symptom diary — Bristol stool, bowel frequency, flare log for GI; itch scale, eczema severity index for skin.
• Vitamin D and zinc — Common deficiencies in IBD; check and correct.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

Anti-inflammatory and repair peptides that sit alongside or overlap with KPV's niche.

Next Steps

Key References

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177.
2. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID: 18092346.
3. Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3:iii52-iii55. PMC2095288.
4. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. PMID: 18612027.
5. Coco R, Plapied L, Pourcelle V, Jérôme C, Brayden DJ, Schneider YJ, Préat V. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int J Pharm. 2013;440(1):3-12. PMID: 22939963.
6. Xiao B, Laroui H, Viennois E, et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014;146(5):1289-1300.e1-19.
7. Viennois E, Ingersoll SA, Ayyadurai S, et al. Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of the Anti-inflammatory PepT1-Mediated Tripeptide KPV in a Murine Model. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357.
8. Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. PMC5498804.
9. Lee S, Lee SJ, Shin H, et al. α-MSH-derived tripeptide KPV reduces TNF-α induced inflammation in keratinocytes via NF-κB pathway modulation. J Dermatol Sci. 2019.
10. Ahmed TJ, Montero-Melendez T, Perretti M, Pitzalis C. Curbing inflammation through endogenous pathways: focus on melanocortin peptides. Int J Inflam. 2013;2013:985815.
11. Singh M, Mukhopadhyay K. Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide. Biomed Res Int. 2014;2014:874610.
12. Bohm M, Brzoska T, Luger TA. Anti-inflammatory effects of alpha-MSH and related peptides: beyond the pharmacophore. Adv Exp Med Biol. 2010;681:55-64.
13. Shi X, Chen X, Gao X, et al. Immobilized α-melanocyte stimulating hormone 10–13 (GKPV) inhibits tumor necrosis factor-α stimulated NF-κB activity. Peptides. 2006.
14. Capsoni F, Ongari AM, Reali E, Catania A. Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Arthritis Res Ther. 2009;11(5):R151. PMID: 19814815.
15. Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of α-MSH-related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010;681:107-116.
16. Getting SJ, Perretti M. The melanocortin peptide HP228 displays protective and anti-inflammatory activity in models of experimental inflammation. Br J Pharmacol. 2000;130(8):1889-1896.
17. Catania A, Airaghi L, Colombo G, Lipton JM. Alpha-melanocyte-stimulating hormone in normal human physiology and disease states. Trends Endocrinol Metab. 2000;11(8):304-308.
18. Kannengiesser K, Lügering A, Maaser C, Domschke W, Luger TA, Kucharzik T. Treatment of murine colitis with the tripeptide KPV-review of recent findings. Falk Symp. 2010.
19. Dalmasso G, Nguyen HT, Yan Y, Charrier-Hisamuddin L, Sitaraman SV, Merlin D. Butyrate transcriptionally enhances peptide transporter PepT1 expression and activity. PLoS One. 2008;3(6):e2476.
20. Xiao B, Ma L, Merlin D. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opin Drug Deliv. 2017;14(1):65-73.